Space-related pharma-motifs for fast search of protein binding motifs and polypharmacological targets by Yi-Yuan Chiu et al.
PROCEEDINGS Open Access
Space-related pharma-motifs for fast search of
protein binding motifs and polypharmacological
targets
Yi-Yuan Chiu1, Chun-Yu Lin1, Chih-Ta Lin1, Kai-Cheng Hsu1, Li-Zen Chang1, Jinn-Moon Yang1,2*
From Asia Pacific Bioinformatics Network (APBioNet) Eleventh International Conference on Bioinformatics
(InCoB2012)
Bangkok, Thailand. 3-5 October 2012
Abstract
Background: To discover a compound inhibiting multiple proteins (i.e. polypharmacological targets) is a new
paradigm for the complex diseases (e.g. cancers and diabetes). In general, the polypharmacological proteins often
share similar local binding environments and motifs. As the exponential growth of the number of protein
structures, to find the similar structural binding motifs (pharma-motifs) is an emergency task for drug discovery (e.g.
side effects and new uses for old drugs) and protein functions.
Results: We have developed a Space-Related Pharmamotifs (called SRPmotif) method to recognize the binding
motifs by searching against protein structure database. SRPmotif is able to recognize conserved binding
environments containing spatially discontinuous pharma-motifs which are often short conserved peptides with
specific physico-chemical properties for protein functions. Among 356 pharma-motifs, 56.5% interacting residues
are highly conserved. Experimental results indicate that 81.1% and 92.7% polypharmacological targets of each
protein-ligand complex are annotated with same biological process (BP) and molecular function (MF) terms,
respectively, based on Gene Ontology (GO). Our experimental results show that the identified pharma-motifs often
consist of key residues in functional (active) sites and play the key roles for protein functions. The SRPmotif is
available at http://gemdock.life.nctu.edu.tw/SRP/.
Conclusions: SRPmotif is able to identify similar pharma-interfaces and pharma-motifs sharing similar binding
environments for polypharmacological targets by rapidly searching against the protein structure database. Pharma-
motifs describe the conservations of binding environments for drug discovery and protein functions. Additionally,
these pharma-motifs provide the clues for discovering new sequence-based motifs to predict protein functions
from protein sequence databases. We believe that SRPmotif is useful for elucidating protein functions and drug
discovery.
Background
During the early drug discovery stage, discovering
potential target proteins for a compound is important to
drug design and to reduce cost and time by detecting
the potential harmful side effects. On the other hand, it
could provide the new usages for old drugs. Recently, to
design a drug inhibiting multiple target proteins (i.e.
polypharmacological targets) builds a new paradigm for
diseases with complex mechanisms, such as cancers and
diabetes. Therefore, discovering polypharmacological
targets, share similar interfaces and are often inhibited
by the same compound, is a valuable issue in under-
standing binding mechanisms and drug development.
To identify the proteins with similar binding sites of a
given protein sequence or structure by searching the
sequence or structure databases has usually used [1-4].
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In general, the proteins (i.e. polypharmacological targets)
bound the same ligand should share similar binding
environments, but they may not have significant evolu-
tionary relationship in both sequences and global struc-
tures. As the exponential growth of the number of
protein structures, protein structures have been pro-
posed to analyze the structural motifs and to describe
the binding environment [5,6]. Most of these studies
(e.g. SPASM [7], Superimpose [8], RASMOT-3D PRO
[9], MultiBind [10], and Wu et al. [11]) search the simi-
lar local structures or binding sites (active sites) based
on only one structural motif. However, a protein-ligand
binding interface usually consists of a set of spatially dis-
continuous structural motifs. For example, two motifs
(i.e. HxGH loop and KMSKS loop) catalyse the amino
acid activation with ATP in class-I aminoacyl-transfer
RNA synthetases [12].
To address these issues, we proposed Space-Related
Pharmamotif (SRPmotif) method to identify the pharma-
interfaces (≥ 2 structural motifs) sharing similar binding
environments from the polypharmacological targets. The
pharma-interface consists of a set of spatially discontinu-
ous peptide segments (i.e. pharma-motifs), which sur-
round the ligand-binding site. By transforming the 3D
structure segments into 1D structural alphabet sequences
through in-house tool (called 3D-BLAST [13,14]), we can
rapidly search the potential target proteins with similar
binding environment against Protein Data Bank (PDB)
[15]. And then a structural alignment tool, such as DALI
[16], was used to precisely locate the possible binding
environment in these protein structures. Experimental
results showed that around 56% interacting residues were
considered as highly conserved in our identified pharma-
motifs. These conserved residues involving in pharma-
motifs often play the key roles for biological functions
and binding mechanisms. Furthermore, these pharma-
motifs can be transferred into sequence-based motifs for
searching similar proteins with local binding-site similar-
ity from protein sequence databases. We believe that
SRPmotif is useful for studying protein functions and dis-
covering the polypharmacological targets for drug design.




Here, we proposed a new concept and a fast method
(SRPmotif) to identify space-related pharma-motifs and
pharma-interfaces for discovering polypharmacological
targets. We considered a pharma-interface as a con-
served binding environment which consists of several
spatially discontinuous pharma-motifs. A pharma-inter-
face can be described as follows: (1) A pharma-interface
is a conserved binding interface of multiple proteins
(called polypharmacological targets) which share similar
interfaces and are often inhibited by the same com-
pound; (2) A pharma-interface consists of a set of
pharma-motifs; (3) A pharma-motif is a short conserved
peptide forming a specific sub-interface with interacting
residues and specific physico-chemical properties. Figure 1
shows the details of our method to identify a pharma-
interface and pharma-motifs from a given complex by the
following steps.
Step 1: Search candidates of polypharmacological targets
To find the candidates of the polypharmacological tar-
gets of a query protein, we firstly transformed the 3D
protein structure of a query complex (i.e. protein and its
binding ligand) into a 1D sequence with 23 states of a
structural alphabet by using in-house tool 3D-BLAST
(Figure 1A) [13,14]. We then identified the binding seg-
ments in the interface of the query complex. For each
segment, its corresponding 1D structural alphabet
sequence was used for rapidly searching structural
alphabet sequence database (SADB) by using 3D-BLAST
and a list of similar protein structures of the query bind-
ing segment was returned within several seconds. For
the tolerance of the flexible binding environment, the
proteins matching more than 75% query segments are
considered as the candidates.
Here, we identified a binding segment (≥ 15 amino
acids) of a given complex by using a contact residue as a
central point to extend seven amino acids forward and
backward. An amino acid is considered as a contact resi-
due if the distance between any atom of this residue and
the atoms of the binding ligand is less than 4Å. Any of
two binding segments with at least one overlapped amino
acid are merged into a single one. As a result, the binding
environment of a given complex is characterized by spa-
tially discontinuous binding segments.
Next, SRPmotif utilizes 3D-BLAST, a fast protein struc-
ture database search, to detect the candidate proteins (i.e.
polypharmacological targets) with similar binding seg-
ments. 3D-BLAST encodes the 3D structures into a serials
of structural alphabets using  and a angles defined in the
DSSP program [17]. Based on the (, a) plot of 674 struc-
tural pairs and a nearest neighbour clustering, a 23-state
structural alphabet represents the profiles of most 3D frag-
ments [14]. A BLOSUM-like substitution matrix, called
structural alphabet substitution matrix (SASM) was devel-
oped by using a method similar to that used to construct
BLOSUM62 [18] based on 674 structural protein pairs.
3D-BLAST searches the SADB using this SASM to quickly
discover homologous structures of a query protein.
Step 2: Establishment of the pharma-interface
In this step, the polypharmacological targets were deter-
mined and used to construct pharma-interface. To deter-
mine the polypharmacological targets through the
candidate proteins identified in the step 1, a structural
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(PDB code: 1QU3A) 
PDB EC CATH GN RMSD AR SI 
1QU3A 6.1.1.5 1.10.730.10, 3.90.740.10 ileS 0 1 100 
1FFYA 6.1.1.5 - ileS 0.4 1 100 
1JZQA 6.1.1.5 1.10.730.10, 3.40.50.620, 3.90.740.10 ileS 1.4 1 31.8 
1WZ2A 6.1.1.4 1.10.730.10, 3.40.50.620, 3.90.740.10 leuS 2 0.99 22.3 
2CT8A 6.1.1.10 3.40.50.620 metG 2 0.99 25.2 
2AG6A 6.1.1.1 1.10.240.10, 3.40.50.620 tyrS 3.1 0.78 16 
1YIDC 6.1.1.2 1.10.240.10 trpS2 3.7 0.77 14 
Establishment of the pharma-interface 
3D-BLAST  + 
RMSD ≤ 2Å  
and 
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Figure 1 Overview of SRPmotif using Isoleucyl-tRNA synthetase-Mupirocin complex as example. (A) Identify polypharmacological
candidates with similar discontinuous binding segments by rapidly searching protein structure databases using 3D-BLAST. The proteins with 75%
similar binding segments are considered as the candidates of the polypharmacological candidates. (B) These candidates with significantly similar
interfaces (RMSD ≤ 2.0Å and average aligned ratio ≥ 0.85) are considered as polypharmacological proteins. (C) The polypharmacological proteins
are used to recognize the conserved segments (pharma-motifs) which can be transformed into 1D sequence patterns based on the multiple
structural alignments. These spatially discontinuous pharma-motifs are formed a pharma-interface for these polypharmacological proteins.
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alignment tool (DALI [16]) was utilized to precisely locate
the possible binding environment in these candidate pro-
tein structures (Figure 1B). The DALI program is a struc-
tural alignment tool based on contact similarity patterns.
Discontinuous binding segments are aligned to a candidate
protein and the value of root mean square deviation
(RMSD) between all binding segments and a candidate
protein is calculated. To estimate opened gaps in a struc-
tural alignment, the value of aligned ratio of a binding seg-
ment is measured. The aligned ratio is defined below:
aligned ratio =
number of aligned residues of candidates
number of residues in queried binding segment
(1)
The range of aligned ratio is from 0 to 1. The RMSD
value and the average aligned ratio of discontinuous bind-
ing segments are used to evaluate the structure similarity
between a query and the candidate proteins. Here, a candi-
date protein is considered as a polypharmacological target
when the value of RMSD is less than 2.0Å and the aligned
ratio is great than 0.85. Consequently, a pharma-interface
is constructed based on the conserved binding interfaces
of polypharmacological targets.
Step 3: Characterization of pharma-motifs
The pharma-interface is composed of a set of pharma-
motifs, short conserved peptides with interacting residues,
to form the binding environment. According to the struc-
ture-based multiple sequence alignment (MSA) of the
pharma-interfaces of a query, pharma-motifs could be
characterized as 1D sequence patterns with the pattern
syntax of PROSITE database [1] (Figure 1C).
In order to encode 1D sequence patterns of pharma-
motifs, structure-based MSAs are used to measure the
sequence conservation. For the position i in a MSA, we
used Rate4Site algorithm [19,20] to evaluate a conserved
score (Spi) by computing the relative evolutionary rate.
The range of Spi is from 1 to 9 and a position with score
of 9 is the most conserved.
In PROSITE syntax, a position labeled as alphabet ‘x’
means that any kinds of amino acids can occur in this
position. Based on 1293 motifs of PROSITE database
(release 20.67 of 02-Nov-2010), the average Spi of encode
‘x’ is 3.67. Here, a position of pharma-motif is encoded as
alphabet ‘x’ when Spi is less than 4. Finally, 1D sequence
patterns of pharma-motifs are characterized.
Non-redundant protein-ligand complex dataset
To verify the pharma-interfaces involving key interacting
residues and functional sites, we collected a protein-ligand
complex dataset which contains 282 FDA approved drugs
recorded in DrugPort of PDBsum [21]. We eliminated
some protein-ligand complexes based on below criteria:
(1) the protein structure is an incomplete structure or a
theoretical model; (2) the co-crystal ligand is metal; (3) the
number of heavy atoms of ligand is less than six heavy
atoms; (4) the co-crystal ligand interacts with multiple
protein chains; (5) proteins have greater than 25%
sequence identity with others or redundant co-crystal
ligands. Final, we selected 89 non-redundant protein-
ligand complexes (called FDA89) with structure-based
classifications (i.e. SCOP [22] and CATH [23]) and all of
the proteins are recorded in the UniProt database [24]
(Table S1 in additional file 1).
Evaluation measures
For evaluating the performance of our method for pre-
dicting polypharmacological targets, the recall and preci-
sion were calculated. Here, we used biological process
(BP) and molecular function (MF) of the Gene Ontology
(GO) [25] to annotate polypharmacological targets. In
addition, the structural classifications, SCOP (version
1.75) and CATH (version 3.4), were also used to annotate
the polypharmacological targets. The recall and precision
are defined in the following:
recall =
true positives




true positives + false positives
(3)
where true positives are predicted as the polypharma-
cological targets of a query protein and have the same
annotation with the query protein; false negatives are
predicted as not polypharmacological targets of a query
protein and have the same annotation with the query
protein; false positives are predicted as the polypharma-
cological targets of a query protein, but the annotations
are different from the query protein.
Results and discussion
Evaluations of SRPmotif
In the FDA89 set, 356 pharma-motifs could be identified
and the average number of pharma-motifs for each pro-
tein-ligand complex is four. To examine whether the
pharma-motifs are similar with the PROSITE motifs, a
pharma-motif is considered consistent with a PROSITE
motif when the intersections of two patterns (i.e. over-
lapped ratio) are greater than the cut-off (a range of
values between 10% and 100%) of the pharma-motif or
the PROSITE motif (Figure S1 in additional file 1). The
overlapped ratio is defined as the maximum value
between the length of the aligned pattern divided by the
length of the pharma-motif and that of the PROSITE
motif. The result shows that the percentage of over-
lapped motifs decreases significantly if the overlapped
ratio ≥ 50%. Here, the cut-off is set to 50%. Among 66
PROSITE motifs in the FDA89 set, our derived pharma-
motifs are consistent with 65% (43/66) PROSITE motifs.
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Moreover, we compared the evolutionary conservation
of the interacting residues with other residues. Figure 2
shows the distributions of the conservation score (Spi)
between the interacting residues and other residues in
356 pharma-motifs. For highly conservation (Spi ≥ 7),
the Spi values of the interacting residues (56.5%) were
significantly higher than those of other residues (41.9%).
In addition, 31.6% interacting residues were conserved
with the highest Spi values. These results show that the
interacting residues involved in pharma-motifs are
highly conserved and encoded as conserved pattern.
Precision and recall rates were utilized to assess the
similarity of biological functions (i.e. BP and MF) and
structural classifications (i.e. SCOP and CATH) between
polypharmacological targets and their query proteins of
protein-ligand complexes. Based on BP and MF annota-
tions, the precision rates are 81.1% and 92.7%, respec-
tively (Table 1). These experimental results show that
polypharmacological targets not only are involved in the
similar cellular process but also perform similar biologi-
cal functions. Moreover, the precision rates are 55.2%
and 79.7% for SCOP and CATH, respectively (Table 1).
In the above results, the polypharmacological targets
without annotations are considered as negatives. The
precision rates are more than 90% when the polypharma-
cological targets without any annotations are removed.
The high precision rates show that polypharmacological
targets of each protein-ligand complex are usually
recorded in the same structure family.
However, the results with low recall rates may imply
that proteins with the same annotation (i.e. biological
function or the structure family) sometimes have the key
difference in protein-ligand binding environments. For
example, viral neuraminidase (NA) of influenza virus is a
drug target for prevention of influenza infection and has
several homologous proteins (e.g. Sialidase 2 (NEU2)) in
the human genome. Both of NA and NEU2 are a type of
glycoside hydrolase enzymes (Enzyme Commission num-
ber (EC) 3.2.1.18). NA (PDB code: 1NNC[26], chain A)
and NEU2 (PDB code: 2F0Z, chain A) have crystal struc-
tures with the same drug, Zanamivir (ZMR, listing name
Relenza), and are classified as identical structure family
in SCOP (b.68.1.1) and CATH (2.120.10.10).
The NEU2 or NA is not the polypharmacological tar-
get of NA-ZMR complex or NEU2-ZMR complex,



















Conserved Score (Spi) 
interacting residues
other residues
Figure 2 Conserved score (Spi) of the residues in the pharma-motifs. The conserved scores (Spi) of 56.5% interacting residues (red) and
41.9% other residues (blue) in the pharma-motifs are more than 7.0.
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of NA-ZMR and NEU2-ZMR complexes, the interacting
residues and identified binding segments of two com-
plexes are different (RMSD of binding segments is 3.8).
Previous experiment results showed that NA is inhibited
by ZMR in nM level (H1N1: 1.56 nM, H3N2: 2.66 nM,
H5N3: 3.97 nM) while NEU2 is inhibited by ZMR in
μM level (16.4 μM) [27]. The proteins in the same
structure family (i.e. SCOP and CATH) might be subdi-
vided to many sub-families by SRPmotif due to different
binding environments. Therefore, the SRPmotif method
is sensitive and precise to identify the pharma-motifs for
describing the binding environment between protein
and ligand.
Example analysis: Isoleucyl-tRNA synthetase and
Mupirocin
Figure 3 shows that the pharma-interface and pharma-
motifs by using the Isoleucyl-tRNA synthetase (ileS) of
Staphylococcus aureus and Mupirocin complex (PDB
code: 1QU3[28], chain A) as the query template. Bacterial
ileS is involved in the incorporation of isoleucine into bac-
terial proteins. Mupirocin is an antibiotic originally iso-
lated from Pseudomonas fluorescens NCIMB 10586. It is
also selective binding to bacterial ileS to achieve bacterios-
tasis at low concentrations and bactericidal effect at high
concentrations against Gram-positive bacteria. For this
protein-ligand complex, SRPmotif yielded 20 polypharma-
cological targets from the PDB database (Table 2). These
polypharmacological targets have similar functions but
belong to different ligases forming aminoacyl-tRNA (EC
6.1.1.*). SRPmotif also detected a protein (i.e. Methionyl-
tRNA synthetase (metG)) recorded in different structure
family with ileS. Figure 3A shows that the superimposition
of binding environments between proteins ileS and metG
(PDB code: 2CT8[29], chain A). In the identified pharma-
motifs, the interacting residues of query complex are
highly conserved and spatially closed (Figure 3B). For
example, the residues H64, G66, and H67 of Pharma-
Motif 1 in ileS (PDB code: 1QU3) are encoded as con-
served positions. Previous study indicated that H-x-G-H
(HxGH loop) involved in Pharma-Motif 1 was a signature
sequence in class-I aminoacyl-transfer RNA synthetases
[12]. Additionally, one PROSITE motif, aminoacyl-transfer
RNA synthetases class-I signature (PS00178), is covered by
Pharma-Motif 1. The pattern encodings are consistent
with the PS00178, especially in interacting residues, such
as residues H64 and G66 of HxGH loop (Figure 3C).
Pharma-Motif 4 contains a highly conserved region (i.e.
K-M-S-K-[ST]-[LK]-G-N) which is not recoded in PRO-
SITE database. This region includes the KMSKS loop (K-
M-S-K-[ST]) and one of residues (i.e. K598) is important
to ATP binding [12,30] (Figure 3B). The conserved resi-
dues, G601 and N602, interact to KMSKS loop by hydro-
gen bonds (Figure 3D). It suggests that two conserved
residues could stabilize the structure of KMSKS loop and
enable K598 to bind ATP. In addition, several residues of
derived pharma-motifs are highly conserved to stabilize
the structure or protein-ligand interaction, such as D75
in Pharma-Motif 1 (Figure 3C) and G586 in Pharma-
Motif 4 (Figure 3B). These results show that SRPmotif
could recognize the proteins with similar functions and
binding motifs, even are recoded in the different struc-
ture families. Furthermore, the pharma-motifs include
the conserved interacting residues on functional sites for
studying protein functions and binding mechanisms.
Example analysis: tyrosine-protein kinase KIT and
Imatinib
Protein kinases play important roles in cell growth and
signal transduction. Protein KIT is one of tyrosine-protein
kinases and a kind of receptor of stem cell factors. Imati-
nib (list name: Gleevec or Glivec) is an inhibitor for tyro-
sine-protein kinases, including KIT, ABL1, ABL2, and
PDGFR. By blocking ATP binding site, Imatinib inhibits
tyrosine-protein kinases and is approved to treat chronic
myelogenous leukemia and gastrointestinal stromal tumor.
Here, we used tyrosine-protein kinase KIT (PDB code:
1T46[31], chain A) and Imatinib complex as query to
search against the PDB database and construct the
pharma-interface and pharma-motifs.
The polypharmacological targets of KIT-Imatinib com-
plex consists of 25 tyrosine-protein kinases. SRPmotif
recognizes the protein CSF1R, which has no crystal struc-
tures of Imatinib binding. Figure 4A presents the residues
interacted with Imatinib by hydrogen bonds in three
structures having co-crystal Imatinib (PDB code: 1T46,
chain A, PDB code: 3GVU, chain A, and PDB code: 2PL0
[32], chain A). These residues (e.g. E640, T670, C673 and
Table 1 Precision and recall of polypharmacological targets using gene ontology (GO) annotations or structure
classifications










Number of positives in
database
Biological process 81.1 31.5 9702 11956 30810
Molecular function 92.7 19.9 11089 11956 55662
SCOP 55.2 29.7 6596 11956 22213
CATH 79.7 12.8 9533 11956 74294
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D810) are conserved in sequence and structure of protein
CSF1R (PDB code: 2OGV[33], chain A). Previous experi-
ment has also showed that CSF1R is inhibited by Imati-
nib in 19nM [34]. It suggests that Imatinib could be
possible to treat acute myeloid leukemia through inhibit-
ing CSF1R.
The pharma-motifs, Pharma-Motif 1 and 2, have over-
lapped with the identical PROSITE motifs (Protein
kinases ATP-binding region signature, PS00107). The
highly conserved regions, [LIQ]-[GY]-x-G-[AQSH]-[FY]-
G-x-V and [VC]-A-[VI]-K, are similar to PS00107 (Figure
S2 in additional file 1, upper side). It also involves to the
GxGxFG motif in P-loop of a kinase [35], which is related
to interact with phosphate of ATP. The Pharma-Motif 4
contains two highly conserved regions, [IV]-H-R-D-[LV]-
[AR]-A-[RA]-N and K-[IV]-x-D-[FY]-[GY]. The former
is alike to the known motif (Tyrosine protein kinases spe-





PROSITE motif: PS00178 





































Isoleucyl-tRNA synthetase (1QU3A)  









Figure 3 The pharma-interface and pharma-motifs of Isoleucyl-tRNA synthetase-Mupirocin complex. (A) The pharma-motif
superimposition between Isoleucyl-tRNA synthetase and its polypharmacological target, Methionyl-tRNA synthetase, is well aligned. These two
proteins are belonging to the different structure families and the pharma-motifs are the color segments. (B) Interacting residues are highly
conserved in these pharma-motifs. The ligands are colored by magenta. (C) Pharma-motif 1 and the corresponding PROSITE motif, PS00178. (D)
Pharma-motif 4 is the ATP binding motif and involves KMSKS loop with two conserved residues (G601 and N602). These two residues stabilize
the KMSKS loop by using hydrogen bonds (green line) with residue K598.
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Ligand SCOP CATH Species Gene
Name
Description RMSD AR SI






ileS Isoleucyl-tRNA synthetase 0 1 100






ileS Isoleucyl-tRNA synthetase 0.4 1 100






ileS Isoleucyl-tRNA synthetase 0.4 1 100
1ileA P56690 6.1.1.5 ZN a.27.1.1, b.51.1.1,
c.26.1.1
1.10.730.10, 3.40.50.620, 3.90.740.10 Thermus thermophilus ileS Isoleucyl-tRNA synthetase 1.4 1 31.8
1jzqA P56690 6.1.1.5 ILA, ZN a.27.1.1, b.51.1.1,
c.26.1.1
1.10.730.10, 3.40.50.620, 3.90.740.10 Thermus thermophilus ileS Isoleucyl-tRNA synthetase 1.4 1 31.8




1.10.730.10, 3.40.50.620, 3.90.740.10 Thermus thermophilus ileS Isoleucyl-tRNA synthetase 1.4 1 31.8
2d5bA P23395 6.1.1.10 ZN a.27.1.1, c.26.1.1 1.10.730.10, 3.40.50.620 Thermus thermophilus metG Methionyl-tRNA
synthetase
1.7 1 26.8
2d54A P23395 6.1.1.10 ZN a.27.1.1, c.26.1.1 1.10.730.10, 3.40.50.620 Thermus thermophilus metG Methionyl-tRNA
synthetase
1.7 1 26.8
1a8hA P23395 6.1.1.10 ZN a.27.1.1, c.26.1.1 1.10.730.10, 2.170.220.10,
3.40.50.620
Thermus thermophilus metG Methionyl-tRNA
synthetase
1.7 1 26.8
1woyA P23395 6.1.1.10 ZN a.27.1.1, c.26.1.1 1.10.730.10, 2.170.220.10,
3.40.50.620
Thermus thermophilus metG Methionyl-tRNA
synthetase
1.8 1 26.8
1li5A P21888 6.1.1.16 ZN a.27.1.1, c.26.1.1 3.40.50.620 Escherichia coli cysS Cysteinyl-tRNA synthetase 1.9 0.99 30.5
1li7A P21888 6.1.1.16 CYS, ZN a.27.1.1, c.26.1.1 3.40.50.620 Escherichia coli cysS Cysteinyl-tRNA synthetase 1.9 0.99 30.5
1li7B P21888 6.1.1.16 CYS, ZN a.27.1.1, c.26.1.1 3.40.50.620 Escherichia coli cysS Cysteinyl-tRNA synthetase 1.9 0.95 30.5
1li5B P21888 6.1.1.16 ZN a.27.1.1, c.26.1.1 3.40.50.620 Escherichia coli cysS Cysteinyl-tRNA synthetase 2 0.95 30.5
1wkbA O58698 6.1.1.4 SO4 - 1.10.730.10, 3.40.50.620, 3.90.740.10 Pyrococcus horikoshii leuS Leucyl-tRNA synthetase 2 0.99 22.3
1wz2A O58698 6.1.1.4 - - 1.10.730.10, 3.40.50.620, 3.90.740.10 Pyrococcus horikoshii leuS Leucyl-tRNA synthetase 2 0.99 21.7
1wz2B O58698 6.1.1.4 - - 1.10.730.10, 3.40.50.620, 3.90.740.10 Pyrococcus horikoshii leuS Leucyl-tRNA synthetase 2 0.99 21.7
2ct8A O67298 6.1.1.10 MSP - 3.40.50.620 Aquifex aeolicus metG Methionyl-tRNA
synthetase
2 0.99 25.2
2ct8B O67298 6.1.1.10 MSP - 3.40.50.620 Aquifex aeolicus metG Methionyl-tRNA
synthetase
2 0.99 25.2






















kinase catalysis, named the catalytic loop in a kinase (Fig-
ure S2 in additional file 1, bottom side). Previous study
has showed that the conserved aspartic acid in the cataly-
tic loop may be important in positioning the substrate
hydroxyl for in-line nucleophilic attack [36] (Figure 4C).
The latter has been reported as conserved peptide, DFG
motif [35], which is the beginning of activation loop of a
kinase. The conformation of DFG motif is relevant to
kinase activation and the conserved aspartic acid binds
directly to the magnesium ion cofactor orienting the g-
phosphate group of ATP for transfer (Figure 4C).
We also observed the conserved lysine in the front of
DFG motif in Pharma-Motif 4. Figure 4B shows that the
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Figure 4 The pharma-interface and pharma-motifs of the tyrosine-protein kinase KIT-Imatinib complex. (A) The four residues (E640, T670,
C673 and D810) of KIT protein (cyan) form hydrogen bonds (green dashed lines) with Imatinib (magenta) and are conserved in this family. (B)
The conserved residue K807 plays an important role to stabilize the kinase structures. (C) The conserved residues in these pharma-motifs are
related to phosphorylation of KIT. Asterisks mark the residues interacting with the ATP with hydrogen bonds.
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interacts many neighbouring residues in space by hydro-
gen bonds, such as E671 in Hinge region, M651, I653,
and N655. The residue V654 close to K807 usually
interacts with inhibitors. It suggests that conserved
K807 could compact the kinases structure to keep the
interaction of V654 and inhibitors. Figure 4C shows that
these conserved residues of the identified pharma-motifs
are related to phosphorylation. For example, the con-
served lysine in Pharma-Motif 2 is helpful for stabilizing
g- and a-phosphate groups of ATP. The conserved glu-
tamic acid in Pharma-Motif 3 is helpful for stabilizing g-
phosphate group of ATP. These results show that
pharma-motifs involved important interacting residues
and conserved positions of the pharma-motifs could
play important roles in protein function and binding
mechanisms.
Computational time
SRPmotif utilizes structural alphabets and 3D-BLAST for
searching similar structure segments within 1 minute on
average. During the construction of a pharma-interface
and pharma-motifs, the computational time for a query
complex depends on the number of polypharmacological
candidates and hit targets. On average, for a query com-
plex, such as Isoleucyl-tRNA synthetase-Mupirocin com-
plex, SRPmotif searches the structure database and
characterizes the pharma-interface and pharma-motifs
within 5 minutes. In some cases, SRPmotif identified
pharma-motifs from over hundreds of target proteins
within 10 minutes. These tests were conducted on a Linux
platform with Intel® Quad-core processors and 8G RAM.
Conclusions
SRPmotif is able to identify similar pharma-interfaces and
pharma-motifs sharing similar binding environments for
polypharmacological targets by rapidly searching against
the protein structure database. The experimental results
demonstrate that the identified pharma-motifs would
comprise key residues and important functional sites.
Pharma-motifs describe the conservations of binding
environments for polypharmacological targets and provide
clues for discovering new sequence-based motifs for pre-
dicting protein functions from protein sequence database.
We believe that SRPmotif is useful for elucidating protein
functions, protein-ligand interactions, and drug discovery.
Additional material
Additional file 1: Supplementary figures and table.
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